Mersana Therapeutics (MRSN)
(Delayed Data from NSDQ)
$2.08 USD
+0.05 (2.46%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $2.08 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MRSN 2.08 +0.05(2.46%)
Will MRSN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MRSN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRSN
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Misses Revenue Estimates
Seer, Inc. (SEER) Reports Q1 Loss, Misses Revenue Estimates
MRSN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Moderna (MRNA) Reports Q1 Loss, Tops Revenue Estimates
Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Lags Revenue Estimates
Other News for MRSN
Mersana Therapeutics to Present at Upcoming Investor Conferences
SBRA, GH and CRBU are among after hour movers
Mersana Therapeutics: On Hold While Waiting For Any Positive News
Truist Financial Sticks to Its Buy Rating for Mersana Therapeutics (MRSN)
Analysts Are Bullish on These Healthcare Stocks: Mersana Therapeutics (MRSN), Insulet (PODD)